{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03145181",
            "orgStudyIdInfo": {
                "id": "CR108206"
            },
            "secondaryIdInfos": [
                {
                    "id": "2016-002122-36",
                    "type": "EUDRACT_NUMBER"
                },
                {
                    "id": "64007957MMY1001",
                    "type": "OTHER",
                    "domain": "Janssen Research & Development, LLC"
                },
                {
                    "id": "2023-503438-40-00",
                    "type": "REGISTRY",
                    "domain": "EUCT number"
                }
            ],
            "organization": {
                "fullName": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",
            "officialTitle": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody in Subjects With Relapsed or Refractory Multiple Myeloma",
            "acronym": "MajesTEC-1",
            "therapeuticArea": [
                "Other"
            ],
            "study": "dose-escalation-study-of-teclistamab-a-humanized-bcma-bispecific-antibody-in-participants-with-relapsed-or-refractory-multiple-myeloma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true,
                "nctId": "NCT05463939",
                "statusForNctId": "APPROVED_FOR_MARKETING"
            },
            "startDateStruct": {
                "date": "2017-05-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2021-11-09",
                "type": "ACTUAL"
            },
            "completionDateStruct": {
                "date": "2026-07-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-04-28",
            "studyFirstSubmitQcDate": "2017-05-08",
            "studyFirstPostDateStruct": {
                "date": "2017-05-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.",
            "detailedDescription": "The study will be conducted in 2 parts, separately for IV and SC administration: dose escalation (Part 1) and dose expansion (Part 2). It will evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity of Teclistamab administered to adult participants with relapsed or refractory multiple myeloma. The overall safety of the study drug will be assessed by physical examinations, Eastern Cooperative Oncology Group performance status, laboratory tests, vital signs, electrocardiograms, adverse event monitoring, and concomitant medication usage. Disease evaluations will include peripheral blood and bone marrow assessments at screening (performed within 28 days) and to confirm stringent complete response (sCR), complete response (CR), or relapse from CR. The end of study (study completion) is defined as 2 years after the last participant in Part 3 has received his or her initial dose of teclistamab. Study record NCT04557098 is Phase 2 part of this study and study record NCT03145181 is Phase 1 part of this study."
        },
        "conditionsModule": {
            "conditions": [
                "Hematological Malignancies"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 282,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Dose Escalation (IV)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Teclistamab intravenously (IV).",
                    "interventionNames": [
                        "Drug: Teclistamab (IV)"
                    ]
                },
                {
                    "label": "Part 2: Dose Expansion (IV)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Teclistamab IV.",
                    "interventionNames": [
                        "Drug: Teclistamab (IV)"
                    ]
                },
                {
                    "label": "Part 1: Dose Escalation (SC)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Teclistamab subcutaneously (SC).",
                    "interventionNames": [
                        "Drug: Teclistamab(SC)"
                    ]
                },
                {
                    "label": "Part 2: Dose Expansion (SC)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Teclistamab SC.",
                    "interventionNames": [
                        "Drug: Teclistamab(SC)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Teclistamab (IV)",
                    "description": "Participants will receive IV infusion of Teclistamab.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation (IV)",
                        "Part 2: Dose Expansion (IV)"
                    ],
                    "otherNames": [
                        "JNJ-64007957"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Teclistamab(SC)",
                    "description": "Participants will receive SC injection of Teclistamab.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation (SC)",
                        "Part 2: Dose Expansion (SC)"
                    ],
                    "otherNames": [
                        "JNJ-64007957"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose Limiting Toxicity (DLT)",
                    "description": "The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and defined as any of the following events: hematological / non hematological toxicity of Grade 3 or higher.",
                    "timeFrame": "Up to Day 28"
                },
                {
                    "measure": "Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability",
                    "description": "An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.",
                    "timeFrame": "Up to 7 years and 3 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Teclistamab Serum Concentrations",
                    "description": "Concentration assessment will be done to evaluate the effect of Teclistamab.",
                    "timeFrame": "Up to 8 weeks"
                },
                {
                    "measure": "Number of Participants with Teclistamab Antibodies",
                    "description": "Antibodies to Teclistamab will be assessed to evaluate potential immunogenicity.",
                    "timeFrame": "Up to 8 weeks"
                },
                {
                    "measure": "Preliminary Antitumor Activity of Teclistamab at the RP2D(s) in Part 2",
                    "description": "Preliminary antitumor activity of Teclistamab will be done using the International Myeloma Working Group (IMWG) response criteria.",
                    "timeFrame": "Up to End of Treatment (Approximately 91 days)"
                },
                {
                    "measure": "Biomarker Assessment",
                    "description": "Biomarker assessment may be done to evaluate the effect of Teclistamab.",
                    "timeFrame": "Up to 8 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Documented diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria\n* Measurable multiple myeloma that is relapsed or refractory to established therapies with known clinical benefit in relapsed/refractory multiple myeloma or be intolerant of those established multiple myeloma therapies, and a candidate for Teclistamab treatment in the opinion of the treating physician. Prior lines of therapy must include a proteasome inhibitor, an immunomodulatory drug and anti-CD38 monoclonal antibody in any order during the course of treatment. Participants who could not tolerate a proteasome inhibitor or immunomodulatory drugs and an anti-CD38 monoclonal antibody are allowed\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Female participants of childbearing potential must use acceptable method of contraception\n* Participants must sign an ICF indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study. Consent is to be obtained prior to the initiation of any study-related tests or procedures that are not part of standard-of-care for the participant's disease\n\nExclusion Criteria:\n\n* Prior treatment with any B cell maturation antigen (BCMA) targeted therapy\n* Prior antitumor therapy as follows, before the first dose of study drug: Targeted therapy, epigenetic therapy, or treatment with an investigational drug or used an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less; Monoclonal antibody treatment for multiple myeloma within 21 days; Cytotoxic therapy within 21 days; Proteasome inhibitor therapy within 14 days; Immunomodulatory agent therapy within 7 days; Gene modified adoptive cell therapy (example, chimeric antigen receptor modified T cells, natural killer \\[NK\\] cells) within 3 months; Radiotherapy within 14 days or focal radiation within 7 days\n* Toxicities from previous anticancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy\n* Received a cumulative dose of corticosteroids equivalent to \\>= 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication)\n* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Contact",
                    "role": "CONTACT",
                    "phone": "844-434-4210",
                    "email": "Participate-In-This-Study@its.jnj.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janssen Research & Development, LLC Clinical Trial",
                    "affiliation": "Janssen Research & Development, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Colorado Blood Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Levine Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Centre hospitalier Lyon-Sud",
                    "status": "RECRUITING",
                    "city": "Pierre Benite cedex",
                    "zip": "69495",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.7009,
                        "lon": 4.82511
                    }
                },
                {
                    "facility": "CHRU Tours Hopital Bretonneau",
                    "status": "RECRUITING",
                    "city": "Tours",
                    "zip": "37044",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.38333,
                        "lon": 0.68333
                    }
                },
                {
                    "facility": "VU Medisch Centrum",
                    "status": "RECRUITING",
                    "city": "Amsterdam",
                    "zip": "1081 HV",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "Hosp. Univ. Germans Trias I Pujol",
                    "status": "RECRUITING",
                    "city": "Badalona",
                    "zip": "08916",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.45004,
                        "lon": 2.24741
                    }
                },
                {
                    "facility": "Hosp Clinic de Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08036",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Clinica Univ. de Navarra",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Hosp Clinico Univ de Salamanca",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                },
                {
                    "facility": "Haematology Centre, R 51",
                    "status": "RECRUITING",
                    "city": "Stockholm",
                    "zip": "SE-141 86",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 59.33258,
                        "lon": 18.0649
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35749004",
                    "type": "DERIVED",
                    "citation": "Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, Elsayed Y. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Target Oncol. 2022 Jul;17(4):433-439. doi: 10.1007/s11523-022-00893-y. Epub 2022 Jun 24. Erratum In: Target Oncol. 2022 Sep;17(5):609. doi: 10.1007/s11523-022-00904-y."
                },
                {
                    "pmid": "35661166",
                    "type": "DERIVED",
                    "citation": "Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martinez-Lopez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5."
                },
                {
                    "pmid": "34388396",
                    "type": "DERIVED",
                    "citation": "Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10."
                },
                {
                    "pmid": "32956453",
                    "type": "DERIVED",
                    "citation": "Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonca M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, Gaudet F. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma",
                    "url": "https://clinicaltrials.gov/ct2/show/NCT04557098"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "Belgium"
            ]
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematological Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}